LEO Pharma Presents 3.5 Year Interim Safety & Efficacy Data in P-III (ECZTEND) Trial of Adbry (tralokinumab-ldrm) for Atopic Dermatitis at AAD 2022
Shots:
- The P-III (ECZTEND) extension trial evaluates Adbry (300mg, q2w) vs PBO + TCS in 1400+ patients with AD who participated in the prior tralokinumab-ldrm monothx. trials
- The interim safety analysis showed that the overall safety profile was consistent with that observed in parent trials with no new safety signals & an interim efficacy analysis showed a sustained improvement in extent & severity of AD, itch severity & QoL for ~3yrs.
- From the cohort of 616 patients, 85.1% achieved 75% improvement in EASI-75, 50.5% achieved IGA 0/1 indicating clear or almost clear skin, improvements in itch & QoL as measured by 60.6% achieved a Worst Weekly Pruritus NRS score & 76.4% achieved a DLQI score
Ref: Leo | Image: Leo
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
